Clinical profile and treatment utilisation based on HLA-B*27 status in axial spondyloarthritis: results from ASAS-PerSpA study.

Haseeb Ahmad Chaudhary Clementina López Medina Muhammad Asim Khan Maxime DougadosMarina Magrey

Published in: RMD open (2023)

HLA-B*27 (-) axSpA patients had a longer delay in diagnosis, more frequently had peripheral arthritis, enthesitis, IBD, psoriasis, and were more often treated with csDMARDs compared to HLA-B*27 (+) subgroup.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
rheumatoid arthritis
prognostic factors
peritoneal dialysis
ankylosing spondylitis
randomized controlled trial
systemic lupus erythematosus
patient reported
open label
phase iii